|1.||Maggi, Carlo Alberto: 3 articles (11/2005 - 06/2003)|
|2.||Culman, J: 2 articles (05/2010 - 01/2000)|
|3.||Cho, S-H: 2 articles (08/2009 - 12/2006)|
|4.||Kim, Y-K: 2 articles (08/2009 - 12/2006)|
|5.||Oh, S-Y: 2 articles (08/2009 - 12/2006)|
|6.||Min, K-U: 2 articles (08/2009 - 12/2006)|
|7.||Kim, Y-Y: 2 articles (08/2009 - 12/2006)|
|8.||Kim, T-B: 2 articles (08/2009 - 12/2006)|
|9.||Park, H-K: 2 articles (08/2009 - 12/2006)|
|10.||von Mentzer, Bengt: 2 articles (08/2008 - 03/2008)|
|1.||Asthma (Bronchial Asthma)
09/01/2006 - "To evaluate neurokinin 2 receptor (NK2R) gene polymorphisms in association with the clinical phenotype of TDI-induced asthma, 70 TDI-induced occupational asthma (TDI-OA)patients, 59 asymptomatic exposed controls (AEC), and 93 unexposed healthy controls (NC) were enrolled in the study. "
07/01/2009 - "NK-2 receptors have been implicated in playing a pathophysiological role in asthma. "
07/01/2000 - "This increased airway responsiveness, increased neurokinin-2 receptor expression, and decreased beta(2)-adrenergic receptor density may be relevant to asthma exacerbation."
03/01/2007 - "We tested the safety, tolerability, and pharmacologic and biological efficacy of a tachykinin NK(1)/NK(2) receptor antagonist, AVE5883, in patients with asthma in two double-blind, placebo-controlled crossover studies. "
01/01/2005 - "Based on our data and previous studies in asthma, it can be hypothesized that this direct NKA-induced bronchoconstrictor response may be mediated by predominant stimulation of the tachykinin NK-2 receptors on airway smooth muscle cells."
12/03/2001 - "The tachykinins SP and NKA, released from terminals of primary sensory neurons in peripheral tissues, cause all the major signs of inflammation (neurogenic inflammation) by means of activation of NK(1) and NK(2) receptors. "
02/01/2001 - "When stimulated, excitatory nonadrenergic noncholinergic (e-NANC) nerves locally release tachykinins like Neurokinin (NK) A and Substance P, causing neurogenic inflammation and airway obstruction via activation of specific NK-1 and NK-2 receptors. "
05/01/2008 - "This study aimed to 1) assess whether substance P (SP) acts via neurokinin (NK)-1 and NK-2 receptors to stimulate neurogenic inflammation (indicated by formation of ICAM-1 expression and oxidative stress) following oil smoke exposure (OSE) in rats; and 2) determine if pretreatment with antioxidants ameliorates the deleterious effects of OSE. "
|3.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
08/15/2008 - "Tachykinin NK(2) receptor antagonists are potentially beneficial in treating various disorders including irritable bowel syndrome, urinary incontinence, depression and anxiety. "
05/01/2009 - "Ibodutant (MEN15596, [1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) is a tachykinin NK(2) receptor (NK(2)R) antagonist currently under phase II clinical trials for irritable bowel syndrome. "
03/17/2008 - "The results demonstrate that NK(1) and NK(2) receptors are involved in stress-related colonic motor alterations and visceral pain responses in gerbils and that combined antagonism provides enhanced inhibition of visceral pain responses. "
02/01/1996 - "In summary, spinal neurokinin-2 receptors are important in the generation of pain in the normal and inflamed joint."
11/01/2007 - "Neurokinin-2 receptor levels correlate with intensity, frequency, and duration of pain in chronic pancreatitis."
05/01/2010 - "Blockade of NK(1) and NK(2) receptors attenuated the formalin-induced increases in mean arterial pressure and heart rate, adrenaline and ACTH concentrations in plasma, and completely abolished the pain-induced c-Fos expression in corticotrophin-releasing hormone neurones localised in the parvocellular division of the PVN. "
01/01/2000 - "Our results show that (i) the modified formalin test elicited an intense grooming behaviour and expression of c-Fos in numerous forebrain and brainstem areas, (ii) both tachykinin receptor antagonists were able to attenuate the behavioural response to pain and to reduce the formalin-induced c-Fos expression in some, but not all, brain areas, and (iii) the neurokinin-1 antagonist, RP 67580, was more effective in inhibiting the behavioural response to formalin and the pain-induced activation of c-Fos than the antagonist for neurokinin-2 receptors, SR 48968, indicating that neurokinin-1 receptors are preferentially activated in neurokinin-containing pathways responding to noxious stimuli. "
|1.||Neurokinin-1 Receptors (Neurokinin 1 Receptor)
|4.||SR 48968 (saredutant)
|5.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|8.||Tachykinin Receptors (Tachykinin Receptor)